# A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

> **NCT05156983** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 328 (estimated)

## Conditions studied

- Coagulation Disorder

## Interventions

- **DRUG:** TAK-330
- **DRUG:** SOC 4F-PCC

## Key facts

- **NCT ID:** NCT05156983
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-24
- **Primary completion:** 2028-04-12
- **Final completion:** 2028-04-12
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156983, "A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05156983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*